All Health Care News
Top stories summarized by our editors
5/21/2018

The PDD Blue Light Flexible Video Cytoscopy System has been launched by Karl Storz for use in the detection of bladder cancer. The release followed the recent FDA approval of a supplemental new drug application and a premarket approval supplement to add use of the cytoscopy system to the indication of the company's Blue Light Cystoscopy with Cysview.

More Summaries:
Karl Storz
5/21/2018

Patients with malignant pheochromocytomas and paragangliomas had significantly reduced tumors in the lungs, liver and lymph nodes, significantly increased progression-free survival, better blood pressure and diabetes remission after receiving cabozantinib, researchers reported at the American Association of Clinical Endocrinologists' annual meeting. The findings also showed that cabozantinib stabilized disease among five of eight patients with predominant bone metastases on FDG-PET scans and was well-tolerated among all patients.

5/21/2018

A German study in the Journal of Nuclear Medicine showed that a breakthrough method combining PET/CT and a physiologically based pharmacokinetic/dynamic model using Lu-177 PSMA for imaging and therapy yielded a one plus or minus 40% relative deviation of predicted and measured tumor volume among patients with metastatic castration-resistant prostate cancer undergoing radioligand therapy, indicating the approach's feasibility and acceptable accuracy. "Future work including a refined model, definition of subpopulations and use of SPECT/CT data will help to improve further the prediction accuracy of the model," researchers wrote.

Full Story:
Health Imaging online
5/21/2018

Two clinical studies evaluating JNJ-54861911, or atabecestat, for Alzheimer's disease were stopped by Johnson & Johnson's Janssen Biotech because of an unfavorable risk-benefit profile for the beta-site amyloid precursor protein-cleaving enzyme inhibitor. Screening, randomization and dosing of atabecestat will be stopped by the company in a Phase IIb/III study in patients with late-onset preclinical-stage Alzheimer's and in a midstage European long-term safety study.

5/21/2018

China's State Drug Administration accepted under priority review status Innovent Biologics' new drug application for IBI308, or sintilimab, which is being developed as a treatment of relapsed or refractory classical Hodgkin lymphoma. In a midstage trial, the candidate achieved a disease control rate of 97.9% and an overall response rate of 79.2%.

Full Story:
BioCentury
More Summaries:
Innovent Biologics
5/21/2018

There was a more than 10% increase in compensation for primary care physicians during the past five years, with the increases in median pay differing significantly across US states, according to a report from the Medical Group Management Association. Wyoming had the largest increase in physician compensation at 41%, followed by Maryland at 29%, Louisiana at 27%, Missouri at 24% and Mississippi at 21%, while physicians in the District of Columbia were paid the least with $205,776 in median total compensation.

5/21/2018

A report from the Robert Wood Johnson Foundation and the Urban Institute estimates that 4.5 million people would gain health care coverage if the 19 states that have not fully expanded Medicaid did so next year. The move would raise federal health care spending as much as $37.8 billion, while state Medicaid spending would grow as much as $3.0 billion, but the additional spending would be completely or mostly offset by savings in other areas, the report indicates.

Full Story:
Forbes
5/21/2018

Artificial intelligence can help radiologists curb administrative tasks and increase patient interaction, as well as address increasing volumes of radiological interpretations, limited autonomy, uneven distribution of work and declining reimbursements, but they should combine the technology with their talent to yield these benefits, according to a Deloitte paper. "With new technologies and diagnostic capabilities, radiologists will need to learn new skills and capabilities to adapt," researchers wrote.

Full Story:
Health Imaging online
More Summaries:
AI
5/21/2018

CMS Administrator Seema Verma warned Medicare Part D plan sponsors that they could face compliance action if they don't take steps to ensure that enrollees are paying for the lowest price available for medications, noting that plans should require network pharmacies to reveal any difference between the price of a drug under Part D and the price for its cheapest generic version. In a letter sent to plan sponsors, Verma said contract language prohibiting such disclosures is "unacceptable and contrary to our efforts to promote drug price transparency and lower drug prices."

Full Story:
Healthcare Finance
More Summaries:
Seema Verma
5/21/2018

Pediatricians should warn at-risk children and their parents against watching the Netflix series "13 Reasons Why," adhere to American Academy of Pediatrics recommendations that all patients ages 12 and older be screened for depression, and ask adolescents about their media consumption, according to an article in Pediatrics. Researchers said a review of records at one health system found that in the six months after the first season aired, the show was mentioned over 60 times by 31 youths, three-quarters of whom were receiving care related to a suicide attempt.

Full Story:
Reuters